Factor H inhibits complement activation induced by liposomal and micellar drugs and the therapeutic antibody rituximab in vitro.

Mészáros, Tamás and Csincsi, Ádám and Uzonyi, Barbara and Hebecker, Mario and Fülöp, Tamás and Erdei, Anna and Szebeni, János and Józsi, Mihály (2016) Factor H inhibits complement activation induced by liposomal and micellar drugs and the therapeutic antibody rituximab in vitro. NANOMEDICINE: NANOTECHNOLOGY BIOLOGY AND MEDICINE, 12 (4). pp. 1023-1031. ISSN 1549-9634

Preview

Text Nano_CARPA_Real.pdf Download (797kB) | Preview

Abstract

Hypersensitivity reactions to particulate drugs can partly be caused by complement activation and represent a major complication during intravenous application of nanomedicines. Several liposomal and micellar drugs and carriers, as well as therapeutic antibodies, were shown to activate complement and induce complement activation-related pseudoallergy (CARPA) in model animals. To explore the possible use of the natural complement inhibitor factor H (FH) against CARPA, we examined the effect of FH on complement activation induced by CARPAgenic drugs. Exogenous FH inhibited complement activation induced by the antifungal liposomal Amphotericin-B (AmBisome), the widely used solvent of anticancer drugs Cremophor EL, and the anticancer monoclonal antibody rituximab in vitro. An engineered form of FH (mini-FH) was more potent inhibitor of Ambisome-, Cremophor EL- and rituximab-induced complement activation than FH. The FH-related protein CFHR1 had no inhibitory effect. Our data suggest that FH or its derivatives may be considered in the pharmacological prevention of CARPA.

Actions (login required)

Edit Item